Ultraleap raised €72M in a Series D+ round in Nov 2021. The company is based in Bristol, UK. Investors in the round: British Patient Capital’s “Future Fund: Breakthrough”, CMB International, IP Group and 2 others. Data as of 6 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
